REMICADE®, a prescription biologic for treatment of gastroenterological, dermatological, & rheumatic conditions. See full Product & Safety Info, including Boxed Warnings.. .
Perfekt, din titel innehåller mellan 10 och 70 tecken.
Bra, din metabeskrivning innehåller mellan 70 och 160 tecken.
Vi hittade 40 bilder på denna webbsida. 29 alt attribut är tomma eller saknas. Lägg till alternativ text så att sökmotorer enklare kan förstå innehållet i dina bilder.
Idealisk! Den här sidans text till HTML-kod förhållande är mellan 25 och 70 procent.
Perfekt, inga Flash-innehåll har upptäckts på denna sida.
Synd, du har Iframes på webbsidorna vilket innebär att innehållet i en Iframe inte kan indexeras.
| title | REMICADE® (infliximab) |
|---|---|
| description | REMICADE® (infliximab) Official Healthcare Professional Website. See full Product & Safety Information, including Boxed Warnings. |
Interna Länkar 72.22%
Externa Länkar [Passing Juice 27.78%]
Externa Länkar [noFollow 0%]
| Anchor | Link | Typ | Juice |
|---|---|---|---|
| Important Safety Information | http://remicadehcp.com/important-safety-information.html | Interna | Passing Juice |
| Prescribing Information | http://janssenlabels.com/package-insert/product-monograph/prescribing-inf | Externa | Passing Juice |
| Medication Guide | http://janssenlabels.com/package-insert/product-patient-information/REMIC | Externa | Passing Juice |
| For US Patients & Caregivers | https://remicade.com | Externa | Passing Juice |
| REMICADE® clinical information | http://remicadehcp.com/# | Interna | Passing Juice |
| Adult: moderately to severely active Crohn's disease | http://remicadehcp.com/crohns-disease/clinical-information.html | Interna | Passing Juice |
| Pediatric: moderately to severely active Crohn's disease | http://remicadehcp.com/pediatric-crohns-disease/clinical-information.html | Interna | Passing Juice |
| Adult: moderately to severely active ulcerative colitis | http://remicadehcp.com/ulcerative-colitis/clinical-information.html | Interna | Passing Juice |
| Pediatric: moderately to severely active ulcerative colitis | http://remicadehcp.com/pediatric-ulcerative-colitis/clinical-information. | Interna | Passing Juice |
| Adult: moderately to severely active rheumatoid arthritis | http://remicadehcp.com/rheumatoid-arthritis/clinical-information.html | Interna | Passing Juice |
| Adult: active ankylosing spondylitis | http://remicadehcp.com/ankylosing-spondylitis/clinical-information.html | Interna | Passing Juice |
| Adult: active psoriatic arthritis | http://remicadehcp.com/psoriatic-arthritis/clinical-information.html | Interna | Passing Juice |
| Adult: chronic severe plaque psoriasis | http://remicadehcp.com/plaque-psoriasis/clinical-information.html | Interna | Passing Juice |
| Dosing & administration | http://remicadehcp.com/#Item-2 | Interna | Passing Juice |
| Adult: moderately to severely active Crohn's disease | http://remicadehcp.com/crohns-disease/dosing-administration.html | Interna | Passing Juice |
| Pediatric: moderately to severely active Crohn's disease | http://remicadehcp.com/pediatric-crohns-disease/dosing-administration.htm | Interna | Passing Juice |
| Adult: moderately to severely active ulcerative colitis | http://remicadehcp.com/ulcerative-colitis/dosing-administration.html | Interna | Passing Juice |
| Pediatric: moderately to severely active ulcerative colitis | http://remicadehcp.com/pediatric-ulcerative-colitis/dosing-administration | Interna | Passing Juice |
| Adult: moderately to severely active rheumatoid arthritis | http://remicadehcp.com/rheumatoid-arthritis/dosing-administration.html | Interna | Passing Juice |
| Adult: active ankylosing spondylitis | http://remicadehcp.com/ankylosing-spondylitis/dosing-administration.html | Interna | Passing Juice |
| Adult: active psoriatic arthritis | http://remicadehcp.com/psoriatic-arthritis/dosing-administration.html | Interna | Passing Juice |
| Adult: chronic severe plaque psoriasis | http://remicadehcp.com/plaque-psoriasis/dosing-administration.html | Interna | Passing Juice |
| Access & support | http://remicadehcp.com/access-support.html | Interna | Passing Juice |
| Resources | http://remicadehcp.com/resources.html | Interna | Passing Juice |
| STELARA (ustekinumab) | https://stelarahcp.com/ | Externa | Passing Juice |
| SIMPONI ARIA (golimumab) | https://simponiariahcp.com/ | Externa | Passing Juice |
| TREMFYA (guselkumab) | https://tremfyahcp.com | Externa | Passing Juice |
| Please see full Prescribing Information for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion. | https://tremfyahcp.com/ | Externa | Passing Juice |
| SIMPONI (golimumab) | https://simponihcp.com/ | Externa | Passing Juice |
| FIND OUT WHAT ACTIONS YOU CAN TAKE | http://remicadehcp.com/access-support.html#is-your-patient-being-asked-to | Interna | Passing Juice |
| HELP PATIENTS FIND AN INFUSION CENTER | https://2infuse.com/ | Externa | Passing Juice |
| TALK TO YOUR PATIENTS ABOUT REMICADE® | http://remicadehcp.com/resources.html#resources-for-you-patients | Interna | Passing Juice |
| Legal Notice | http://remicadehcp.com/legal-notice.html | Interna | Passing Juice |
| Privacy Policy | http://remicadehcp.com/privacy-policy.html | Interna | Passing Juice |
| Contact Us | http://remicadehcp.com/contact-us.html | Interna | Passing Juice |
| Do Not Sell My Personal Information | https://janssen.com/us/privacy-request/ | Externa | Passing Juice |
15 Längd
Perfekt. Din deklarerade teckenuppsättning är UTF-8.
Bra. Ditt angivna språk är EN. 
Bra! Vi har inte hittat några föråldrad HTML taggar i din HTML.
Bra, din webbplats har en favicon.
Bra! Ingen e-postadress har hittats i klartext.
Denna sida drar inte nytta utav Dublin Core.
Vi kunde inte hitta CSS för utskrifter.
over 2.8 million patients have been prescribed remicade® worldwide*2, over 2.8 million patients have been prescribed remicade® worldwide*2, induction dosing, maintenance dosing, induction dosing, maintenance dosing, induction dosing, maintenance dosing, induction dosing, maintenance dosing, induction dosing, maintenance dosing, induction dosing, maintenance dosing, induction dosing, maintenance dosing, induction dosing, maintenance dosing, remicade®—approved in the united states since 19981, remicade®—approved in the united states since 19981, clinical data for remicade®, access, affordability, and treatment support for your patients, resources for your practice and your patients, targan study design, accent i study design, sonic study design6,9, reach study design, act 1 study design, act 2 study design, pediatric ulcerative colitis trial study design, express study design1,5, express ii study design1,6, spirit study design1,7, assert study design5,6, impact 2 study design5,6, start study design3, attract study design1,5, aspire study design1,5, dosing for adults with moderately to severely active crohn’s disease, dosing for adults with moderately to severely active ulcerative colitis, dosing for pediatric patients with moderately to severely active ulcerative colitis, dosing for pediatric patients with moderately to severely active crohn’s disease, dosing for chronic severe plaque psoriasis, dosing for moderately to severely active rheumatoid arthritis, dosing for active psoriatic arthritis, dosing for active ankylosing spondylitis, important safety information for remicade® (infliximab), serious infections, malignancies, contraindications, hepatitis b reactivation, hepatotoxicity, heart failure, hematologic events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurologic events, concurrent administration with other biologics, autoimmunity, vaccinations and use of live vaccines/therapeutic infectious agents, adverse reactions, crohn’s disease, pediatric crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, important safety information for remicade® (infliximab), serious infections, malignancies, contraindications, hepatitis b reactivation, hepatotoxicity, heart failure, hematologic events, hypersensitivity, cardiovascular and cerebrovascular reactions during and after infusion, neurologic events, concurrent administration with other biologics, autoimmunity, vaccinations and use of live vaccines/therapeutic infectious agents, adverse reactions, crohn’s disease, pediatric crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, placebo, active, induction, adult, every, prior, randomized, infusion, infection, disease, moderately, colitis, crohns, regimen, reported, therapy, infections, response, dose, symptoms, cases, remicade, pediatric, weeks, safety, signs, study, maintenance, information, week, including, treated, mgkg, received, patients, risk, severely, clinical, treatment, reactions, given, arthritis, mtx, malignancies, remission, psoriasis, ulcerative, during, severe, been, remicadehcp.com.
